News

ArcheMedX Achieves Data Milestone Modeling Over 25 Million Learning Behaviors

ArcheMedX, a behavioral science-based learning company providing a smarter way to predict and improve clinical team performance, recently passed a significant data milestone. PRWeb - Charlottesville, VA March 24, 2022 Today, the Company announced its clinician learning and predictive analytics platform, Ready, has now surpassed more than 25 million essential learning behaviors

Posted on 24 Mar 2022
By ArcheMedX Team
In News

ArcheMedX Releases New Findings at CNS Summit Revealing Clinician Readiness

The area of clinical research known as CNS (central nervous system conditions) is commonly cited for its complexity and the subjective nature of many assessment tools. CNS clinicians therefore must commit to tackling unique challenges affecting their patients and the research they conduct. It should be no surprise that the life

Posted on 4 Nov 2021
By ArcheMedX Team
In Clinical Research Blog, News

AMA Recognizes ArcheMedX’s COVID-19 Report on Virtual Tech in Clinical Trials for Excellence

Today, ArcheMedX announced that its 2020 industry report, “COVID-19's Impact on Virtual Tech in Clinical Trials, was honored with a prestigious American Marketing Association (AMA) award. Every year, the AMA honors hundreds of stand-out marketers through awards programs presented by the AMA Foundation, local professional chapters, and academic special interest groups.

Posted on 4 Oct 2021
By Collated Resource
In News

Webinar: Transforming Study Start Up to Reduce Clinical Trial Site Burden

Watch on Demand Now! Clinical trials are more complex than ever. And 85% of them are delayed. More screening criteria, more procedures, new vendor systems and tools, and more data. So who bears the burden of all this progress? Sites. Increased site burden means degraded performance, more delays, and more problems for you. But

Posted on 15 Sep 2021
By ArcheMedX Team
In Clinical Research Blog, News

ValenzaBio Selects Ready by ArcheMedX to Expedite Biomarker Study

CHARLOTTESVILLE, VA Apr. 21, 2021 -- ArcheMedX announced today that ValenzaBio, a biotech focused on developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, has selected Ready, the industry’s leading clinical trial learning and predictive analytics platform, to optimize performance on its upcoming Phase II study. ValenzaBio is deploying Ready to

Posted on 21 Apr 2021
By ArcheMedX Team
In News

Clinical Operations

Commercial Teams

Resources

Medical Education

About Us

Connect with us

ArcheMedX Achieves Data Milestone Modeling Over 25 Million Learning Behaviors

ArcheMedX Releases New Findings at CNS Summit Revealing Clinician Readiness

AMA Recognizes ArcheMedX’s COVID-19 Report on Virtual Tech in Clinical Trials for Excellence

Webinar: Transforming Study Start Up to Reduce Clinical Trial Site Burden

ValenzaBio Selects Ready by ArcheMedX to Expedite Biomarker Study

Social

Recent News

Raising the Bar: Why Quality and Training Will Define Your Success Under ICH E6(R3)

From Outcomes to Insights: 4 Best Practices in Outcomes Storytelling

Contact Us

300 E Main Street, Suite 101 Charlottesville, VA 22902

+1-434-260-1850

Email Us

About Us

Subscribe

Request a Demo